Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 4/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.35 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.31 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6464825 | 1.00 | P2RY2 (0.42) | P2RY2SLC29A1CA1CA2PLA2G1B | |
| SCHEMBL6060585 | 0.84 | LMNA (0.45) | SLC29A1LMNATHRBMTORMDM2 | |
| SCHEMBL25407209 | 0.83 | LMNA (0.44) | SLC29A1LMNATHRBMTORMDM2 | |
| SCHEMBL28645147 | 0.81 | LMNA (0.46) | SLC29A1LMNATHRBMTORMDM2 | |
| SCHEMBL5562051 | 0.78 | PDE4D (0.40) | SLC29A1LMNATHRBMTORMDM2 | |
| Guanidine SCHEMBL28644548 | 0.77 | LMNA (0.43) | SLC29A1LMNATHRBMTORMDM2 | |
| SCHEMBL15239320 | 0.76 | LMNA (0.47) | SLC29A1LMNATHRBMTORMDM2 | |
| SCHEMBL2546576 | 0.75 | SLC28A1 (0.43) | P2RY2SLC29A1 | |
| SCHEMBL8520771 | 0.75 | P2RY2 (0.42) | P2RY2CA1CA2PLA2G1BATG4B | |
| SCHEMBL17748428 | 0.74 | SLC28A1 (0.42) | P2RY2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6846810-B2 | Hepatitits virus | ROCHE PALO ALTO LLC (US) | 2005-01-25 | — | — | US | disclosed |
| US-20040121980-A1 | Antiviral nucleoside derivatives | ROCHE PALO ALTO LLC | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121980-A1 | Antiviral nucleoside derivatives | SLC29A1, SAMHD1, NUDT1 | P2RY2 750/4885SLC29A1 1/4885CA1 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.